# Simple Fed-Batch Strategy for Production of Capsular Polysaccharide by Haemophilus influenzae b at Pilot Scale

**Authors:** Mateus Ribeiro da Silva, Silvia Maria Ferreira Albani, Joaquin Cabrera-Crespo, José Geraldo da Cruz Pradella, Mickie Takagi

PMC · DOI: 10.3390/bioengineering13020249 · Bioengineering · 2026-02-20

## TL;DR

This paper presents a simplified and scalable method for producing a key vaccine antigen from Haemophilus influenzae b, which could help in cost-effective vaccine manufacturing.

## Contribution

The study introduces a technically accessible fed-batch strategy for high-yield production of Hib capsular polysaccharide suitable for pilot scale.

## Key findings

- Exponential fed-batch with cell recycling achieved the highest PRP concentration of 1879.28 mg/L.
- Constant fed-batch with increased air flow reached 1706.40 mg PRP/L and was successfully scaled up to 80 L.
- Oxygen availability was identified as a critical parameter for improving PRP production.

## Abstract

Haemophilus influenzae b (Hib) is a pathogenic bacterium that causes meningitis worldwide, mainly in children less than two years old. The capsular polysaccharide b (PRP) is an essential antigen for vaccine formulation. This study aimed to develop a high-yield, technically accessible production strategy for PRP production to facilitate vaccine manufacturing in non-profit laboratories. Various fed-batch cultivation strategies were evaluated to address metabolic limitations and identify a robust, simplified process suitable for seamless scale-up to pilot scale. Glucose limitation strategies did not reduce inhibitory acetic acid accumulation due to deficiencies in Hib’s respiratory chain, whereas oxygen availability was identified as critical parameter. Increasing the specific air flow from 0.5 to 1.0 vvm in constant fed-batch (Cfb) resulted in a 33% yield increase, reaching 1706.40 mg PRP.L−1. However, the highest PRP concentration was achieved using exponential fed-batch with cell recycling (EfbCR), resulting in 1879.28 mg PRP.L−1. Although EfbCR offered high productivity, the Cfb strategy emerged to be the most technically feasible and robust solution and was successfully scaled up to an 80 L bioreactor, achieving 1885 mg PRP.L−1. These results advance understanding of PRP production by Hib and provides valuable insight into an efficient and simplified strategy for producing this key/vital vaccine antigen. The findings support the potential for cost-effective local production in public health initiatives.

## Linked entities

- **Diseases:** meningitis (MONDO:0021108)

## Full-text entities

- **Diseases:** infection (MESH:D007239), pneumonia (MESH:D011014), Hib infection (MESH:D006192), epiglottitis (MESH:D004826), meningitis (MESH:D008580), Deficiencies in the respiratory chain (MESH:D028361), injury to (MESH:D014947)
- **Chemicals:** sulfuric acid (MESH:C033158), pO2 (MESH:C093415), ribose (MESH:D012266), Glucose (MESH:D005947), NAD (MESH:D009243), Acetate (MESH:D000085), citric acid (MESH:D019343), CO2 (MESH:D002245), CS (MESH:D002586), carbohydrate (MESH:D002241), PRP (MESH:C008984), S (MESH:D013455), CPRP (-), Hemin (MESH:D006427), NaOH (MESH:D012972), Acetic Acid (MESH:D019342), water (MESH:D014867), TCA (MESH:D014233), MP (MESH:C063925), K2 HPO4 (MESH:C013216), Polysaccharide (MESH:D011134), oxygen (MESH:D010100), hexose (MESH:D006601), NaCl (MESH:D012965), pyruvate (MESH:D019289)
- **Species:** Homo sapiens (human, species) [taxon 9606], Haemophilus influenzae (species) [taxon 727], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Hi [taxon 2008768], Escherichia coli (E. coli, species) [taxon 562]
- **Cell lines:** EfbC1.0 — Homo sapiens (Human), Familial hypertrophic cardiomyopathy type 26, Induced pluripotent stem cell (CVCL_A6XE), HA.L-1 — Helicoverpa armigera (Cotton bollworm), Spontaneously immortalized cell line (CVCL_Z978), Ifb0.2 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_1E78)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938574/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938574/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938574/full.md

---
Source: https://tomesphere.com/paper/PMC12938574